DBNDD1: A Potential Drug Target and Biomarker for Dystrobrevin (Dystrobrevin Binding Protein 1) Domain Containing 1

Target Name: DBNDD1

NCBI ID: G79007

DBNDD1

DBNDD1: A Potential Drug Target and Biomarker for Dystrobrevin (Dystrobrevin Binding Protein 1) Domain Containing 1

Abstract:

Dysbindin (Dystrobrevin Binding Protein 1) domain containing 1 (DBNDD1) is a highly conserved protein that is expressed in various tissues and organs, including brain, heart, and skeletal muscles. It plays a critical role in the regulation of intracellular signaling pathways, including the cAMP/protein kinase (PKA) signaling pathway. DBNDD1 has been implicated in various diseases, including neurodegenerative disorders, myopathies, and cardiomyopathies. In this article, we review the current literature on DBNDD1 and its potential as a drug target and biomarker.

Introduction:

Dysbindin (Dystrobrevin Binding Protein 1) domain containing 1 (DBNDD1) is a protein that is characterized by the presence of a conserved DBNDD1 domain and a unique N-terminal region that contains a putative transmembrane domain (TMD) and a unique C-terminal region that contains a calcineurin-like domain (CUD) and a leucine-rich repeat (LRR) domain. DBNDD1 is expressed in various tissues and organs, including brain, heart, and skeletal muscles, and has been implicated in the regulation of intracellular signaling pathways , including the cAMP/protein kinase (PKA) signaling pathway.

DBNDD1 has been implicated in various diseases, including neurodegenerative disorders, myopathies, and cardiomyopathies. For example, studies have shown that DBNDD1 is overexpressed in neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. Additionally, DBNDD1 has been shown to be involved in the regulation of myopathic diseases, such as dystroglycemia (3) and myopathies. Furthermore, DBNDD1 has been implicated in the regulation of cardiomyopathies, including left ventricular hypertrophy.

Potential therapeutic applications of DBNDD1 as a drug target:

DBNDD1 has been identified as a potential drug target due to its unique structure and its involvement in various diseases. One potential mechanism by which DBNDD1 could be targeted is through its role in the regulation of intracellular signaling pathways, including the cAMP/PKA signaling pathway. Activation of this pathway has been shown to promote the formation of cAMP, which is a key regulator of various cellular processes, including protein synthesis, cell growth, and inflammation.

In addition to its role in intracellular signaling pathways, DBNDD1 has also been shown to play a critical role in the regulation of cellular interactions, including the regulation of cell-cell and cell-tissue interactions. This may be of particular interest in the context of diseases that involve cellular dysfunction, such as neurodegenerative disorders and myopathies.

Potential biomarkers for DBNDD1:

DBNDD1 has also been identified as a potential biomarker for various diseases, including neurodegenerative disorders and myopathies. One potential mechanism by which DBNDD1 could be used as a biomarker is its role in the regulation of intracellular signaling pathways, including the cAMP/PKA signaling pathway. Activation of this pathway has been shown to promote the formation of cAMP, which is a key regulator of various cellular processes, including protein synthesis, cell growth, and inflammation.

In addition to its role in intracellular signaling pathways, DBNDD1 has also been shown to play a critical role in

Protein Name: Dysbindin Domain Containing 1

The "DBNDD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DBNDD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets